Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Sulbactam

Sulbactam

pharmaceutical raw materials
Sulbactam structure

Sulbactam 

structure
  • CAS No:

    68373-14-8

  • Formula:

    C8H11NO5S

  • Chemical Name:

    Sulbactam

  • Synonyms:

    4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-,4,4-dioxide,(2S,5R)-;4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-,4,4-dioxide,(2S-cis)-;CP 45899;Penicillanic acid sulfone;Penicillanic acid 1,1-dioxide;Sulbactam;Penicillanic acid dioxide;Penicillanic acid S,S-dioxide;Betamaze

  • Categories:

    Active Pharmaceutical Ingredients  >  Antibiotics

Description

Sulbactam(Betamaze) is an irreversible β-lactamase inhibitor.Target: β-lactamase; AntibacterialSulbactam is a mechanism-based inhibitor of beta-lactamase enzymes used in clinical practice. sulbactam was the antimicrobial agent responsible for the killing of these organisms [1]. sulbactam may prove effective for non-life-threatening A. baumannii infections. Its role in the treatment of severe infections is unknown. However, the current formulation of sulbactam alone may allow its use at h


Sulbactam is a member of penicillanic acids.|Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.|Sulbactam is a beta Lactamase Inhibitor. The mechanism of action of sulbactam is as a beta Lactamase Inhibitor.|Sulbactam is a semi-synthetic beta-lactamase inhibitor. The beta-lactam ring of sulbactam irreversibly binds to beta-lactamase at or near its active site, thereby blocking enzyme activity and preventing metabolism of other beta-lactam antibiotics by the enzyme. Combining this agent with a beta-lactamase susceptible antibiotic, such as penicillins or a cephalosporin, to treat infections caused by beta-lactamase producing organisms, results in a decreased turnover rate of the beta-lactamase sensitive antibiotic and enhances its antibacterial activity.|A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.

Sulbactam Basic Attributes

233.24

233.24

269-878-2

S4TF6I2330

DTXSID1023605

C61957

J - Antiinfectives for systemic use

2941109900

Characteristics

100

-1

white to tan lyophilized powder

1.6±0.1 g/cm3

148-151 °C

356°C at 760 mmHg

297.1±30.1 °C

1.605

soluble in water at 18mg/ml

−20°C

D20 +251° (c = 0.01 in pH 5.0 buffer)

Safety Information

NONH for all modes of transport

3

22

24/25

Xn

P301 + P312 + P330

H302

|Danger|H302 (78%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P272, P280, P285, P301+P312, P302+P352, P304+P341, P321, P330, P333+P313, P342+P311, P363, and P501|Aggregated GHS information provided by 51 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Approximately 38% reversibly bound to human serum protein.

Drug Information

Sulbactam is currently available in combination products with ampicillin. Within this formulation it is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp. Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).|FDA Label|Treatment of bacterial infections

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)|Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)

Peak serum concentrations are reached almost immediately following a 15-minute intravenous infusion of sulbactam + ampicillin. Mean peak serum levels for sulbactam range from 48 to 88 mcg/mL following intravenous administration of 2000 mg of ampicillin plus 1000 mg sulbactam. After an intramuscular injection of 1000 mg ampicillin plus 500 mg sulbactam, peak sulbactam serum levels ranging from 6 to 24 mcg/mL are attained.|Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration.|Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration.

~1 hr

Sulbactam is an irreversible inhibitor of β-lactamase; by binding and inhibiting β-lactamase produced by bacterial cells, sulbactam is thereby able to prevent it from reducing antibiotic activity. Although sulbactam alone possesses little useful antibacterial activity, except against the Neisseriaceae, whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred drug resistance. The presence of sulbactam in formulations with ampicillin effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials. Thus, products with ampicillin + sulbactam possess the properties of a broad-spectrum antibacterial and a beta-lactamase inhibitor.

Bétamaze

Sulbactam Use and Manufacturing

Methods of Manufacturing

Method 1: 6.51g (41mmo1) potassium permanganate is dissolved in 130ml water and 4.95ml glacial acetic acid, and cooled to about 5°C. A solution of 4.58 g (21 mmol) of sodium penicillin dissolved in 50rnl of water at about 5°C was added, and stirred at 5°C for 20 min. Remove the cold bath, add solid sodium bisulfite until the color of potassium permanganate disappears, and then filter. To the filtrate was added half of its volume of saturated sodium chloride aqueous solution to adjust the pH to 1.7. The acidic aqueous solution was extracted with ethyl acetate. The extract was dried and concentrated under reduced pressure to obtain 3.47 g of sulbactam. The acidic aqueous solution after extraction was saturated with sodium chloride and extracted with ethyl acetate. The extract was dried and concentrated to obtain 0.28 g of sulbactam. A total of 3.75g sulbactam was obtained with a yield of 78%. Method 2: Use 6-APA as raw material. Mix sodium bromide and sulfuric acid (hydrobromic acid can also be used), add 67APA at 0°C with stirring. After 6-APA is completely dissolved, add an aqueous solution of sodium nitrite dropwise. After the completion of the reaction, the reaction is below 4°C. The aqueous layer was separated and extracted twice with dichloromethane. The extract was used to extract oil again, and then washed with water. Add equal amount of water to neutralize to neutral. The aqueous solution containing 6-bromopenicillanic acid was separated and used directly in the next reaction. Potassium permanganate, water and glacial acetic acid are mixed, and the aqueous solution of 6-bromopenicillanic acid obtained in the previous reaction is added under stirring at 0°C. React below 5°C for 1h. Add sodium bisulfite to decolorize, then add chloroform, adjust to pH=2 with sulfuric acid. The chloroform layer was separated, and the aqueous layer was extracted with chloroform. The chloroform layers were combined, washed with water and dried. Chloroform was distilled off under reduced pressure, that is, crystals were precipitated, collected by filtration, washed with chloroform, and dried to obtain 6-bromopenicillane sulfonic acid. 6-Bromopenicillin sulfone acid is mixed with water, adjusted to neutrality with sodium hydroxide, 10% palladium-carbon and disodium hydrogen phosphate are added for hydrogenolysis. Filter, add ethyl acetate to the filtrate, and adjust to pH=2 with sulfuric acid. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with water, dried and concentrated under reduced pressure to obtain yellowish crystals, which were washed with ethyl acetate and dried in vacuo to obtain sulbactam, which can be recrystallized from ethyl acetate-petroleum ether. Method 3: Add bromine, sulfuric acid and sodium nitrite to methylene chloride at 5°C. Then add 6-APA in batches at 4 to 10°C. After stirring at 5°C, sodium bisulfite solution was added dropwise at 5~15°C until the bromine color disappeared, forming a pale yellow solution. The organic layer was separated and the aqueous layer was extracted with dichloromethane. The organic layers were combined and washed with brine to obtain a dibromide in dichloromethane, which was used directly in the next reaction. Water was added to the dichloromethane solution of the above dibromide, and sodium hydroxide solution was added dropwise until Ph=7.0. Separate the water layer and extract the organic layer with water. The extract and the water layer were combined, and potassium permanganate solution was added dropwise to the water layer at -5°C with stirring. Add ethyl acetate and adjust to pH=1.23 with hydrochloric acid. Below 10°C, the sodium bisulfite solution was added dropwise to the formed two-phase solution, and the pH value was maintained at 1.25 to 1.35 with hydrochloric acid. The aqueous layer was saturated with sodium chloride and separated, and extracted with ethyl acetate. After the extract and the organic layer were combined, washed with brine, dried, and filtered to obtain an ethyl acetate solution containing the oxidation product, which was directly used in the next reaction. The above ethyl acetate solution, saturated sodium bicarbonate solution and 5% palladium-carbon were hydrogenated under a hydrogen pressure of about 0.35 MPa. Filter, cool to about 5°C, and adjust pH to 1.2 with hydrochloric acid. After the aqueous layer was saturated with sodium chloride, it was extracted with ethyl acetate. The extract and the organic layer were combined, dried, and concentrated under reduced pressure to obtain crude sulbactam in 57.5% yield. Method 4: Take penicillin G as raw material, oxidize m-chloroperoxybenzoic acid to sulfone, and then hydrolyze to obtain sulbactam.

Uses

A β-lactamase inhibitor.

Human Drugs -> EU pediatric investigation plans

Computed Properties

Molecular Weight:233.24
XLogP3:-1
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:1
Exact Mass:233.03579362
Monoisotopic Mass:233.03579362
Topological Polar Surface Area:100
Heavy Atom Count:15
Complexity:446
Defined Atom Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Downstream Products

Price Analysis

Make your Sulbactam purchase based on the price and market insights! ECHEMI provides professional market insights with prices for you to make a better choice. Learn more on Sulbactam prices .

Recommended Suppliers of Sulbactam

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.